In Vitro Drug Repurposing: Focus on Vasodilators

Data de publicação:

Autores da FMUP

  • Francisco Aguiar Vasques Novoa Faria

    Autor

  • Nuno Filipe De Sousa Vale

    Autor

Participantes de fora da FMUP

  • Ribeiro, Eduarda
  • Costa, Barbara

Unidades de investigação

Abstract

Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context of cancer, drug repurposing can lead to the discovery of new treatments that can target specific cancer cell lines and improve patient outcomes. Vasodilators are a class of drugs that have been shown to have the potential to influence various types of cancer. These medications work by relaxing the smooth muscle of blood vessels, increasing blood flow to tumors, and improving the delivery of chemotherapy drugs. Additionally, vasodilators have been found to have antiproliferative and proapoptotic effects on cancer cells, making them a promising target for drug repurposing. Research on vasodilators for cancer treatment has already shown promising results in preclinical and clinical studies. However, additionally research is needed to fully understand the mechanisms of action of vasodilators in cancer and determine the optimal dosing and combination therapy for patients. In this review, we aim to explore the molecular mechanisms of action of vasodilators in cancer cell lines and the current state of research on their repurposing as a treatment option. With the goal of minimizing the effort and resources required for traditional drug development, we hope to shed light on the potential of vasodilators as a viable therapeutic strategy for cancer patients.

Dados da publicação

ISSN/ISSNe:
2073-4409, 2073-4409

Cells  Multidisciplinary Digital Publishing Institute (MDPI)

Tipo:
Review
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 7

Citações Recebidas na Scopus: 7

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • vasodilators; repurposing drugs; in vitro

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Comparação de escala de qualidade de vida na insuficiência cardíaca com fração de ejeção reduzida quando realizada no domicílio ou na consulta hospitalar.

Investigador Principal: Francisco Aguiar Vasques Novoa Faria

Estudo Observacional Académico (QualidadeIC) . 2021

Citar a publicação

Partilhar a publicação